
|Videos|August 2, 2022
Available Genomic Tests for Clinically Localized Prostate Cancer
Author(s)Stephen J. Freedland, MD
A review of the currently available genomic testing options for patients with clinically localized prostate cancer and the NCCN and AUA/ASTRO recommendations based on risk group.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
2
Amy E. Krambeck, MD, on choosing between CVAC and FANS for suction-based ureteroscopy
3
Urocross shows sustained benefit through 24 months post-removal
4
Study suggests tamsulosin deprescribing may be appropriate for select men with BPH
5














